ANTX - AN2 Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

223.4M

Cash

95.26M

Avg Qtr Burn

-10.39M

Short % of Float

1.95%

Insider Ownership

39.96%

Institutional Own.

54.72%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Epetraborole Details Mycobacterium avium complex lung disease, Lung disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.